In 60 remission-phase patients (30 RRMS, 30 SPMS), Mann-Whitney tests showed RRMS had higher IL-17 (4.20Β±4.57 vs 1.32Β±0.80 pg/mL, p=0.003), higher IFN-Ξ³ (8.12Β±6.96 vs 5.12Β±3.92 pg/mL, p=0.013), and lower TGF-Ξ²1 (14.06Β±4.12 vs 19.91Β±10.21 ng/mL, p=0.029) than SPMS; the remaining 8 cytokines did not differ. EDSS correlated negatively with IL-17 (Rho β0.335) and IFN-Ξ³ (Rho β0.277) and positively with TGF-Ξ²1 (Rho 0.352). The authors interpret this as compartmentalized peripheral inflammation in the relapsing phase, consistent with progressive-stage inflammation becoming sequestered behind a repaired blood-brain barrier .
Note: TGF-Ξ²1 plotted as pg/mL (ng/mL Γ1000); log scale needed due to 4 orders of magnitude range. Only IL-17, IFN-Ξ³, TGF-Ξ²1 differed significantly.
Three design weaknesses limit causal interpretation. First, SPMS patients were ~16 years older (56.4 vs 40.8) and more disabled (EDSS 5.6 vs 1.6); immunosenescence alters Th17/Treg balance, and the authors' own citation of this literature acknowledges age as a confounder without statistically adjusting for it . Second, 40/60 patients were on disease-modifying drugs; the treated-subset comparison preserved group differences but the untreated comparison (n=5 RRMS) was severely underpowered. Third, multiple comparisons across 11 cytokines and many subgroups (active/not-active, MRI activity, treatment strata) raise p-hacking risk β only 3 of ~11 primary tests survived, and 'active MRI' IFN-Ξ³ (n=8) and SPMS IL-10 (n=5) findings are fragile.
Context supports the direction of the IL-17 finding: a 2017 meta-analysis (12 studies) found elevated serum IL-17 in MS vs controls (SMD 2.48) but with IΒ²=96.4% heterogeneity, indicating the field's cytokine measurements are highly inconsistent . Conversely, an RRMS-focused study found IL-17 and IFN-Ξ³ below detection in most patients, questioning whether plasma levels capture CNS inflammation at all β a direct challenge to this paper's assay sensitivity assumptions.
Longitudinal within-patient sampling across RRMSβSPMS conversion, age-matched and treatment-matched cohorts, and head-to-head assay validation (ELISA vs multiplex with detection limits reported) would disprove or confirm the phase-specific cytokine signature. The paper's cross-sectional snapshot cannot distinguish whether cytokine differences cause progression phase, mark it, or are epiphenomena of age and treatment.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.